Research programme: ROCK inhibitors - Devgen

Drug Profile

Research programme: ROCK inhibitors - Devgen

Alternative Names: CDE 5110; CDE 6963

Latest Information Update: 09 Dec 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Devgen
  • Class
  • Mechanism of Action Rho-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Chronic obstructive pulmonary disease; Inflammatory bowel diseases

Most Recent Events

  • 05 Nov 2008 Discontinued - Preclinical for Chronic obstructive pulmonary disease in Belgium (unspecified route)
  • 05 Nov 2008 Discontinued - Preclinical for Inflammatory bowel disease in Belgium (unspecified route)
  • 08 May 2007 Preclinical trials in Inflammatory bowel disease in Belgium (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top